Evidence map›Paper›PMID 31636172›Full record

Trial reportDiabetes2020

Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors.

Jordi Merino, Kathleen A Jablonski, Josep M Mercader, Steven E Kahn, Ling Chen, Maegan Harden, Linda M Delahanty, Maria Rosario G Araneta, Geoffrey A Walford, Suzanne B R Jacobs and 5 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Clinical utility of polygenic risk scores for coronary artery disease.Nature reviews. Cardiology · 2022 · on this map
    Review
  13. Observational
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Jordi MerinoCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA.ORCID 0000-0001-8312-1438
Kathleen A JablonskiThe Biostatistics Center, Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
Josep M MercaderCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Steven E KahnDivision of Metabolism, Endocrinology and Nutrition, VA Puget Sound Health Care System and University of Washington, Seattle, WA.ORCID 0000-0001-7307-9002
Ling ChenCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Maegan HardenGenomics Platform, Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA.
Linda M DelahantyDiabetes Unit, Massachusetts General Hospital, Boston, MA.
Maria Rosario G AranetaDepartment of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA.
Geoffrey A WalfordCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Suzanne B R JacobsCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Uzoma N IbebuoguDivision of Cardiovascular Diseases, Department of Medicine, The University of Tennessee Health Science Center, Memphis, TN.
Paul W FranksGenetic & Molecular Epidemiology Unit, Lund University Diabetes Centre, Malmo, Sweden.ORCID 0000-0002-0520-7604
William C KnowlerDiabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ.ORCID 0000-0002-7004-5197
Jose C FlorezORCID 0000-0002-1730-9325
Diabetes Prevention Program Research Group
Broad Institute · USHarvard University · USMilken Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Tennessee Health Science Center · USUniversity of Washington · USMassachusetts General Hospital · USUniversity of California San Diego · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Post-DDP Follow-up StudyU01DK048413 · NIDDK · UNIVERSITY OF WASHINGTON · PI KAHN, STEVEN EMANUEL · 1994 to 2021
$13.7M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048397 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1994 to 2021
$12.0M
NIDDM PRIMARY PREVENTION TRIAL (DPT 2)U01DK048404 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1994 to 2021
$11.6M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048339 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ARANETA, MARIA ROSARIO GORREZ, MUDALIAR, SUNDER · 1994 to 2022
$11.4M
NIDDM PRIMARY PREVENTION TRIALU01DK048412 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VENDITTI, ELIZABETH MARY · 1994 to 2021
$11.4M
TITLE OMITTEDU01DK048349 · NIDDK · YESHIVA UNIVERSITY · PI CRANDALL, JILL P · 1994 to 2021
$11.0M
PRIMARY PREVENTION TRIALU01DK048443 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WATSON, KAROL E · 1994 to 2021
$10.2M
Post-DPP Follow-up StudyU01DK048375 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DABELEA, DANA · 1994 to 2022
$10.0M
Post-Diabetes Prevention Program (DPP)U01DK048381 · NIDDK · UNIVERSITY OF CHICAGO · PI EHRMANN, DAVID A · 1994 to 2021
$9.6M
Post DPP Follow-up StudyU01DK048434 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GOLDBERG, RONALD B · 1994 to 2022
$9.3M
NCRR NIH HHS M01 RR016587NIDDK NIH HHS K24 DK110550NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK111022NIDDK NIH HHS R01 DK072041NIDDK NIH HHS R01 DK078907NIDDK NIH HHS U01 DK048339NIDDK NIH HHS U01 DK048349NIDDK NIH HHS U01 DK048375NIDDK NIH HHS U01 DK048377NIDDK NIH HHS U01 DK048381NIDDK NIH HHS U01 DK048397NIDDK NIH HHS U01 DK048400NIDDK NIH HHS U01 DK048404NIDDK NIH HHS U01 DK048406NIDDK NIH HHS U01 DK048407NIDDK NIH HHS U01 DK048412NIDDK NIH HHS U01 DK048413NIDDK NIH HHS U01 DK048434NIDDK NIH HHS U01 DK048437NIDDK NIH HHS U01 DK048443NIDDK NIH HHS U01 DK048468NIDDK NIH HHS U01 DK048485NIDDK NIH HHS U01 DK048489NIDDK NIH HHS U01 DK048514
6 · The paper itself

Abstract

Coronary artery disease (CAD) is more frequent among individuals with dysglycemia. Preventive interventions for diabetes can improve cardiometabolic risk factors (CRFs), but it is unclear whether the benefits on CRFs are similar for individuals at different genetic risk for CAD. We built a 201-variant polygenic risk score (PRS) for CAD and tested for interaction with diabetes prevention strategies on 1-year changes in CRFs in 2,658 Diabetes Prevention Program (DPP) participants. We also examined whether separate lifestyle behaviors interact with PRS and affect changes in CRFs in each intervention group. Participants in both the lifestyle and metformin interventions had greater improvement in the majority of recognized CRFs compared with placebo (

Indexed as

Gene-Environment InteractionPrediabetic StatePreventive Health ServicesAdultCardiovascular DiseasesCoronary Artery DiseaseDiabetes Mellitus, Type 2ExerciseExercise TherapyFemaleGenetic Predisposition to DiseaseHumansLife StyleMaleMetabolic SyndromeMetforminMetformin

Identifiers

PMID31636172
PMCPMC6925585
OpenAlexW2981933241

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.